

## Kimtrak<sup>®</sup> (tebentafusp-tebn) – New orphan drug approval

- On January 26, 2022, [Immunocore announced](#) the FDA approval of [Kimtrak \(tebentafusp-tebn\)](#), for the treatment of HLA-A\*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
- Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye. Although it is the most common primary intraocular malignancy in adults, the diagnosis is rare, and up to 50% of people with uveal melanoma will eventually develop metastatic disease.
- Kimtrak is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Kimtrak specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma.
- The efficacy of Kimtrak was established in IMCgp100-202, a randomized, open-label study in 378 patients with metastatic uveal melanoma. Patients were randomized to receive Kimtrak or investigator's choice of [Keytruda<sup>®</sup> \(pembrolizumab\)](#), [Yervoy<sup>®</sup> \(ipilimumab\)](#), or [dacarbazine](#). The major outcome was overall survival (OS). Additional efficacy outcomes were progression-free survival (PFS) and objective response rate (ORR).
  - Median OS was 21.7 months for Kimtrak vs. 16 months for investigator's choice (hazard ratio [HR] 0.51, 95% CI: 0.37, 0.71;  $p < 0.0001$ ).
  - Median PFS was 3.3 months for Kimtrak vs. 2.9 months for investigator's choice (HR 0.73, 95% CI: 0.58, 0.94;  $p = 0.0139$ ).
  - ORR was 9.1% (95% CI: 5.9, 13.4) and 4.8% (95% CI: 1.8, 10.1) for Kimtrak and investigator's choice, respectively.
- Kimtrak carries a boxed warning for cytokine release syndrome (CRS).
- Additional warnings and precautions for Kimtrak include skin reactions, elevated liver enzymes, and embryo-fetal toxicity.
- The most common adverse reactions ( $\geq 30\%$ ) with Kimtrak use were CRS, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, and vomiting. The most common laboratory abnormalities ( $\geq 50\%$ ) were decreased lymphocyte count, increased creatinine, increased glucose, increased aspartate aminotransferase, increased alanine aminotransferase, decreased hemoglobin, and decreased phosphate.
- The recommended intravenous dose of Kimtrak is 20 mcg on day 1, 30 mcg on day 8, 68 mcg on day 15, and 68 mcg once every week thereafter. Treatment should continue until unacceptable toxicity or disease progression occur.
  - Patients should be selected for treatment based on a positive HLA-A\*02:01 genotyping test. An FDA-approved test for the detection of HLA-A\*02:01 genotyping is not currently available.

- Immunocore plans to launch Kimmtrak within weeks. Kimmtrak will be available as a 100 mcg/0.5 mL single-dose vial.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2022 Optum, Inc. All rights reserved.